AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29234503 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral cholecalciferol loading dose (10,000 IU/kg, maximum of 400,000 IU)
Number of subjects: 67
Study 29234503 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 67
Study 29234571 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-37 serum levels measured in stroke patients
Number of subjects: 12
Study 29234571 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-37 urine levels measured in stroke patients
Number of subjects: 12
Study 29234571 — intervention group
Group type: EXPERIMENTAL
Intervention: Trends in serum and urine IL-37 levels
Number of subjects: 12
Study 29234955 — intervention group
Group type: EXPERIMENTAL
Intervention: End of treatment measures of mental health status, work ability, generalized self-efficacy, and expectations of future work ability.
Number of subjects: 106
Study 29234955 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy of future work ability improvement or positivity from before to the end of treatment.
Number of subjects: 106
Study 29235062 — intervention group
Group type: EXPERIMENTAL
Intervention: First vismodegib course (FVC)
Number of subjects: 6
Study 29235062 — intervention group
Group type: EXPERIMENTAL
Intervention: Second vismodegib course (SVC)
Number of subjects: 6
Study 29235365 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination therapy with 20 mg azilsartan, 5 mg amlodipine, and 12.5 mg hydrochlorothiazide (AZL/AML/HCTZ)
Number of subjects: 341
Study 29235365 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination therapy with AZL/AML/HCTZ
Number of subjects: 341
Study 29235365 — intervention group
Group type: COMPARATOR
Intervention: AZL/AML therapy
Number of subjects: 341
Study 29236734 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried Lactobacillus plantarum 299v (Lp299v), 1010 cfu
Number of subjects: 42
Study 29236734 — intervention group
Group type: COMPARATOR
Intervention: Control (meal without Lp299v)
Number of subjects: 42
Study 29236912 — intervention group
Group type: EXPERIMENTAL
Intervention: Underwater treadmill test
Number of subjects: 40
Study 29236912 — intervention group
Group type: COMPARATOR
Intervention: Land treadmill test
Number of subjects: 40
Study 29237053 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous-wave alcohol use
Number of subjects: 0
Study 29237053 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy episodic drinking
Number of subjects: 0
Study 29237053 — intervention group
Group type: EXPERIMENTAL
Intervention: Eleventh grade social jetlag
Number of subjects: 0
Study 29237053 — intervention group
Group type: EXPERIMENTAL
Intervention: Eleventh grade chronotype and social jetlag
Number of subjects: 0
Study 29237284 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity during migraine attacks
Number of subjects: 132
Study 29237444 — intervention group
Group type: EXPERIMENTAL
Intervention: INDI collaborative care model implementation strategy
Number of subjects: 0
Study 29237444 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparable areas)
Number of subjects: 0
Study 29237583 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard referral (counseling and a referral note)
Number of subjects: 1200
Study 29237583 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard referral plus SMS text message (short message service, SMS)
Number of subjects: 1200
Study 29237583 — intervention group
Group type: COMPARATOR
Intervention: SMS text message
Number of subjects: 1200
Study 29237583 — intervention group
Group type: COMPARATOR
Intervention: One-time financial incentive (approximately US $4)
Number of subjects: 1200
Study 29237583 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary prevention messaging intervention
Number of subjects: 1200
Study 29237618 — intervention group
Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection (RCI)
Number of subjects: 0
Study 29237655 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitor (ICM) with Confirm Rx implanted subcutaneously after local anaesthesia, monitoring for non-sustained ventricular tachycardia (NSVT) and atrial fibrillation (AF) over 18 months.
Number of subjects: 30
Study 29237801 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative LOC eating
Number of subjects: 0
Study 29237801 — intervention group
Group type: COMPARATOR
Intervention: Presurgical LOC eating
Number of subjects: 0
Study 29237801 — intervention group
Group type: COMPARATOR
Intervention: LOC eating at baseline
Number of subjects: 0
Study 29238851 — intervention group
Group type: EXPERIMENTAL
Intervention: Mocetinostat 90 mg TIW + gemcitabine 1000 mg/m²
Number of subjects: 48
Study 29239002 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg osimertinib once daily
Number of subjects: 31
Study 29239002 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg osimertinib once daily
Number of subjects: 31
Study 29239002 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 31
Study 29239129 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM+
Number of subjects: 86
Study 29239129 — intervention group
Group type: COMPARATOR
Intervention: GDM-
Number of subjects: 86
Study 29239951 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive hemoglobin measurements (SpHb)
Number of subjects: 146
Study 29239951 — intervention group
Group type: COMPARATOR
Intervention: Blood gas hemoglobin measurements
Number of subjects: 146
Study 29239951 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive hemoglobin measurement (SpHb)
Number of subjects: 146
Study 29239951 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Physiology and Chronic Health Evaluation II score
Number of subjects: 146
Study 29239951 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial blood pressure
Number of subjects: 146
Study 29239953 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA (1 g intravenously)
Number of subjects: 70
Study 29239953 — intervention group
Group type: COMPARATOR
Intervention: Control (no TXA)
Number of subjects: 70
Study 29240542 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/d until disease progression, unacceptable toxicity, or patient refusal
Number of subjects: 51
Study 29241084 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 825 mg/m² combined with sorafenib and radiotherapy (45 Gy in 25 fractions over 5 weeks)
Number of subjects: 54
Study 29241084 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase I study to establish maximum tolerated dose
Number of subjects: 54
Study 29241084 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase II study assessing efficacy and safety
Number of subjects: 54
Study 29241485 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein cholesterol (LDL-C) levels
Number of subjects: 1779
Study 29241485 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosylated hemoglobin levels
Number of subjects: 1779
Study 29241640 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CCP positive
Number of subjects: 1309
Study 29241640 — intervention group
Group type: EXPERIMENTAL
Intervention: RF positive
Number of subjects: 1309
Study 29241640 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CCP positive and erosions
Number of subjects: 1309
Study 29241979 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib (100 mg twice per day)
Number of subjects: 124
Study 29242085 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment strategy using multilevel pregnancy test (MLPT) and symptom evaluation
Number of subjects: 343
Study 29242085 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment strategy using MLPT
Number of subjects: 343
Study 29242184 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-segment-elevation myocardial infarction (STEMI)
Number of subjects: 0
Study 29242184 — intervention group
Group type: EXPERIMENTAL
Intervention: non-ST-segment elevation myocardial infarction (non-STEMI)
Number of subjects: 0
Study 29242184 — intervention group
Group type: EXPERIMENTAL
Intervention: non-STEMI
Number of subjects: 0
Study 29242184 — intervention group
Group type: EXPERIMENTAL
Intervention: STEMI
Number of subjects: 0
Study 29242240 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 mapping performed at 2 days and 6 months post-STEMI
Number of subjects: 283
Study 29242352 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified EFFECT score including age, systolic blood pressure, blood urea nitrogen, sodium, cerebrovascular disease, chronic obstructive pulmonary disease, and hemoglobin.
Number of subjects: 1852
Study 29242352 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified EFFECT score
Number of subjects: 1852
Study 29242398 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29242404 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29242845 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (2000 IU/day)
Number of subjects: 50
Study 29242845 — intervention group
Group type: COMPARATOR
Intervention: Control group (dietary instructions)
Number of subjects: 50
Study 29242852 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative mMUD BMT with high-dose posttransplantation cyclophosphamide (PTCy)
Number of subjects: 20
Study 29243075 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg aspirin q.d. for 8 weeks
Number of subjects: 40
Study 29243168 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity engagement
Number of subjects: 20
Study 29243168 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of metastatic prostate cancer and treatment side effects
Number of subjects: 20
Study 29243168 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic barriers to physical activity
Number of subjects: 20
Study 29243168 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to a cancer exercise specialist
Number of subjects: 20
Study 29243222 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (anti-PD-L1 monoclonal antibody)
Number of subjects: 0
Study 29243287 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib 300 mg BID
Number of subjects: 43
Study 29243287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 29243287 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib 300 mg
Number of subjects: 43
Study 29243344 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 118
Study 29243344 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety/Depression
Number of subjects: 118
Study 29243344 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 118
Study 29243344 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSS
Number of subjects: 118
Study 29243344 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Disturbance
Number of subjects: 118
Study 29243546 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer therapy
Number of subjects: 720
Study 29243546 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 720
Study 29243546 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedatives
Number of subjects: 720
Study 29243546 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term prevention medications
Number of subjects: 720
Study 29243546 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 720
Study 29243546 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart medication/anti-hypertensives
Number of subjects: 720
Study 29243796 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol/D-chiro-inositol ratio in follicular fluid
Number of subjects: 19
Study 29243796 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol pre-treatment in women undergoing IVF
Number of subjects: 19
Study 29243796 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower D-chiro-inositol content in follicular fluid
Number of subjects: 19
Study 29243796 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol/D-chiro-inositol ratio
Number of subjects: 19
Study 29244129 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir-based regimen
Number of subjects: 20
Study 29244126 — intervention group
Group type: EXPERIMENTAL
Intervention: PLHIV
Number of subjects: 456
Study 29244126 — intervention group
Group type: COMPARATOR
Intervention: HUCs
Number of subjects: 456
Study 29244149 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab (TCZ-SC) 162 mg each week for ⩾24 weeks as monotherapy
Number of subjects: 1804
Study 29244149 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab (TCZ-SC) 162 mg each week for ⩾24 weeks in combination with csDMARDs
Number of subjects: 1804
Study 29244149 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous tocilizumab (TCZ-SC)
Number of subjects: 1804
Study 29244957 — intervention group
Group type: EXPERIMENTAL
Intervention: ENPP1 mutation treatment (specific intervention details not provided)
Number of subjects: 0
Study 29244957 — intervention group
Group type: COMPARATOR
Intervention: Control group (specific details not provided)
Number of subjects: 0
Study 29245152 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic radiation exposure during percutaneous coronary procedures
Number of subjects: 138
Study 29245310 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib (500 mg qd) plus Irinotecan (340 mg/m or 125 mg/m depending on use of enzyme-inducing antiepileptic drugs) for 6 cycles, followed by maintenance with apatinib.
Number of subjects: 10
Study 29245310 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib plus Irinotecan
Number of subjects: 10
Study 29246128 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal 25(OH)D concentration during pregnancy (≥ 80 nmol/L)
Number of subjects: 723
Study 29246128 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal 25(OH)D concentration in umbilical cord blood (UCB)
Number of subjects: 723
Study 29246128 — intervention group
Group type: COMPARATOR
Intervention: Maternal 25(OH)D concentration
Number of subjects: 723
Study 29246128 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose tolerance test results
Number of subjects: 723
Study 29246134 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing UKA with anterior notch
Number of subjects: 24
Study 29246134 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing UKA with larger anterior notch
Number of subjects: 24
Study 29246134 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing UKA
Number of subjects: 24
Study 29246150 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose lymphocyte immunotherapy
Number of subjects: 64
Study 29246150 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 64
Study 29246151 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy
Number of subjects: 2703
Study 29246151 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy (primary CVD prevention)
Number of subjects: 2703
Study 29246151 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy (secondary CVD prevention)
Number of subjects: 2703
Study 29246151 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with diabetes mellitus
Number of subjects: 2703
Study 29246159 — intervention group
Group type: EXPERIMENTAL
Intervention: MIB-1 proliferation index (Ki-67) ≥10%
Number of subjects: 78
Study 29246159 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥4 mitoses per 10 high power fields
Number of subjects: 78
Study 29246159 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor size larger than 10 cm
Number of subjects: 78
Study 29246159 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 78
Study 29246159 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-free survival
Number of subjects: 78
Study 29246331 — intervention group
Group type: EXPERIMENTAL
Intervention: Class IV obesity
Number of subjects: 2244
Study 29246331 — intervention group
Group type: COMPARATOR
Intervention: Class III obesity
Number of subjects: 2244
Study 29246331 — intervention group
Group type: EXPERIMENTAL
Intervention: Male children
Number of subjects: 2244
Study 29246331 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin levels
Number of subjects: 2244
Study 29246331 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin levels
Number of subjects: 2244
Study 29246331 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline class IV obesity
Number of subjects: 2244
Study 29246331 — intervention group
Group type: COMPARATOR
Intervention: Baseline class III obesity
Number of subjects: 2244
Study 29246331 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in degree of obesity
Number of subjects: 2244
Study 29246428 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) in patients with BAV
Number of subjects: 157
Study 29246428 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) in patients with type 0 BAV
Number of subjects: 157
Study 29246432 — intervention group
Group type: EXPERIMENTAL
Intervention: WTC Health Registry (WTCHR) participants
Number of subjects: 110
Study 29246432 — intervention group
Group type: COMPARATOR
Intervention: Non-WTCHR participants
Number of subjects: 110
Study 29246432 — intervention group
Group type: EXPERIMENTAL
Intervention: Home dust exposure
Number of subjects: 110
Study 29246803 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (starting at 20 mg per day with stepwise dose ramp-up over 5 weeks to 400 mg per day; accelerated dosing schedule for rapidly progressing disease to 400 mg per day by week 3)
Number of subjects: 127
Study 29246803 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (in the main cohort of 43 patients)
Number of subjects: 127
Study 29246803 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (in the expansion cohort of 48 patients)
Number of subjects: 127
Study 29246803 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax
Number of subjects: 127
Study 29246886 — intervention group
Group type: EXPERIMENTAL
Intervention: Travel to India
Number of subjects: 149
Study 29246886 — intervention group
Group type: COMPARATOR
Intervention: No colonization with ESBL-producing bacteria
Number of subjects: 149
Study 29246900 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy with AMT-060 (AAV5 vector with liver-specific promoter)
Number of subjects: 10
Study 29246909 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultimaster drug-eluting stent
Number of subjects: 60
Study 29246916 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and ticagrelor without stenting for ≤1 month
Number of subjects: 53
Study 29246917 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure microcatheter over pressure wire
Number of subjects: 169
Study 29246917 — intervention group
Group type: COMPARATOR
Intervention: Pressure wire alone
Number of subjects: 169
Study 29246923 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive drugs
Number of subjects: 0
Study 29246923 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic drugs
Number of subjects: 0
Study 29246938 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab plus Lenalidomide
Number of subjects: 0
Study 29246938 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29247021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulixertinib (BVD-523) at a recommended phase II dose (RP2D) of 600 mg twice daily
Number of subjects: 135
Study 29247021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulixertinib (BVD-523)
Number of subjects: 135
Study 29247063 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical and systemic tracer of vascular endothelial growth factor A
Number of subjects: 0
Study 29247063 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29247084 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution susceptibility weighted MRI
Number of subjects: 145
Study 29247084 — intervention group
Group type: COMPARATOR
Intervention: DaTSCAN
Number of subjects: 145
Study 29247084 — intervention group
Group type: COMPARATOR
Intervention: Clinical examination
Number of subjects: 145
Study 29247101 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-guided internet-delivered CBT supplemented with group exposure sessions
Number of subjects: 30
Study 29247143 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment before ICH (24.7% prevalence, n=41)
Number of subjects: 166
Study 29247143 — intervention group
Group type: EXPERIMENTAL
Intervention: CAA defined using magnetic resonance imaging markers
Number of subjects: 166
Study 29247524 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical events (time to first occurrence of any event from the composite cardiovascular endpoint of MI, unstable angina with urgent revascularization, stroke, or death from any cause)
Number of subjects: 9225
Study 29247524 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare resource utilization (hospitalization duration and procedures)
Number of subjects: 9225
Study 29247524 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (self-reported health)
Number of subjects: 9225
Study 29247830 — intervention group
Group type: EXPERIMENTAL
Intervention: AUY922 (70 mg/m weekly intravenous)
Number of subjects: 153
Study 29247912 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of small pericardial effusion (SPE)
Number of subjects: 154
Study 29247912 — intervention group
Group type: COMPARATOR
Intervention: No small pericardial effusion (SPE)
Number of subjects: 154
Study 29247976 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffolds (BVS)
Number of subjects: 15
Study 29248236 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar androgen therapy (BAT) with intramuscular testosterone cipionate 400 mg every 28 days until progression and continued luteinising hormone-releasing hormone agonist therapy.
Number of subjects: 30
Study 29248236 — intervention group
Group type: EXPERIMENTAL
Intervention: Rechallenge with oral enzalutamide 160 mg daily after progression on BAT.
Number of subjects: 30
Study 29248241 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoAnchors
Number of subjects: 198
Study 29248241 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 198
Study 29248263 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavirus vaccination
Number of subjects: 2